Patient-Reported Outcomes in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer After First-Line Enfortumab Vedotin ± Pembrolizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
J. Clin. Oncol 2024 Jan 12;[EPub Ahead of Print], MI Milowsky, PH O'Donnell, CJ Hoimes, DP Petrylak, TW Flaig, HH Moon, TW Friedlander, N Mar, RR McKay, S Srinivas, G Gravis, C Ramamurthy, M Bupathi, S Bracarda, P Wright, Z Hepp, AS Carret, Y Yu, R Dillon, R Kataria, JL Beaumont, I Purnajo, JE RosenbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.